FDA Agrees to Review CTI App

Xconomy Seattle — 

Cell Therapeutics, the Seattle-based developer of cancer drugs, said today that the FDA has agreed to review the company’s application to market pixantrone for non-Hodgkin’s lymphoma in the U.S. The company (NASDAQ: CTIC) is seeking an expedited six-month review for the drug, which is sometimes granted for treatments with life-saving potential. The FDA will decide on its deadline for reviewing the Cell Therapeutics application by Sept. 4, the company said. The treatment, a form of anthracycline chemotherapy, was designed to be less toxic to the heart than other drugs in its class.